Axsome Therapeutics (AXSM) News Today $120.36 -8.81 (-6.82%) Closing price 04:00 PM EasternExtended Trading$120.75 +0.39 (+0.32%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Axsome shares fall after ADHD trial resultsMarch 25 at 6:22 PM | investing.comAxsome succeeds in late-stage trial for ADHD therapyMarch 25 at 6:22 PM | msn.comAxsome Therapeutics' ADHD drug meets main goal in late-stage studyMarch 25 at 7:13 AM | reuters.comCibc World Markets Corp Purchases Shares of 3,445 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cibc World Markets Corp acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,445 shares of the company's stock, valued at approxiMarch 25 at 3:53 AM | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Intech Investment Management LLCIntech Investment Management LLC increased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 46.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,028 shares of the company's stock after puMarch 23 at 4:39 AM | marketbeat.comAxsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?March 20, 2025 | finance.yahoo.comPrivium Fund Management B.V. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Privium Fund Management B.V. reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 22.4% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 62,232 shares of the company's stock after selling 18,000 shares during the period. AxsMarch 20, 2025 | marketbeat.comRoyce & Associates LP Boosts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Royce & Associates LP lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 64.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,000 shares of theMarch 20, 2025 | marketbeat.comAxsome Therapeutics management to meet with TruistMarch 19, 2025 | markets.businessinsider.comRaymond James Financial Inc. Purchases Shares of 174,586 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Raymond James Financial Inc. purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 174,586 shares of the cMarch 19, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Charles Schwab Investment Management Inc. increased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,034 shares of the compaMarch 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Purchases New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 73,497 shares of the company's stock, valuedMarch 16, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Great Lakes Advisors LLCGreat Lakes Advisors LLC lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 13,508 shares of the company's stock after selling 3,220 shares during the quartMarch 16, 2025 | marketbeat.comZacks Research Brokers Increase Earnings Estimates for AXSMMarch 16, 2025 | americanbankingnews.comQ1 EPS Forecast for Axsome Therapeutics Raised by AnalystAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at Zacks Research lifted their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a report issued on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will post earningsMarch 15, 2025 | marketbeat.comIs Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?March 14, 2025 | msn.comWhat is Zacks Research's Forecast for AXSM FY2027 Earnings?Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Zacks Research issued their FY2027 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, March 11th. Zacks Research analyst R. DepartmentMarch 14, 2025 | marketbeat.com4,663 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Aigen Investment Management LPAigen Investment Management LP purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,663 shares of thMarch 8, 2025 | marketbeat.comAxsome Therapeutics' (AXSM) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $200.00 price target on shares of Axsome Therapeutics in a research note on Thursday.March 7, 2025 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Position Lessened by Lindbrook Capital LLCLindbrook Capital LLC decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,144 shares of the company's stock after selling 2,March 7, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)March 6, 2025 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by AnalystsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average rating of "Buy" by the fifteen analysts that are currently covering the company, Marketbeat.com reports. Fifteen research analysts have rated the stock with a buy rating. The average 1 year price target among analyMarch 6, 2025 | marketbeat.comAxsome Therapeutics, Inc.: Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USAMarch 5, 2025 | finanznachrichten.deAxsome Therapeutics management to meet with Piper SandlerMarch 5, 2025 | markets.businessinsider.comTorray Investment Partners LLC Has $1.45 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Torray Investment Partners LLC grew its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 45.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,174 shares of the company's stock afMarch 4, 2025 | marketbeat.comUS Bancorp DE Has $11.09 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)US Bancorp DE lessened its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 131,019 shares of the company's stock after selling 2,107March 4, 2025 | marketbeat.comAxsome Therapeutics gets FDA support to submit sNDA for its Alzheimer’s disease agitation treatmentMarch 4, 2025 | msn.comAxsome Therapeutics (NASDAQ:AXSM) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research note on Monday.March 3, 2025 | marketbeat.comAxsome Therapeutics expects to submit sNDA for AXS-05 in Q3March 3, 2025 | markets.businessinsider.comAxsome Therapeutics price target raised to $160 from $132 at BairdMarch 3, 2025 | markets.businessinsider.comAxsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA SubmissionMarch 3, 2025 | finance.yahoo.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $160.00Robert W. Baird raised their price target on Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a report on Monday.March 3, 2025 | marketbeat.comNew York State Common Retirement Fund Purchases 8,843 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)New York State Common Retirement Fund boosted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 64.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,491 shares of tMarch 3, 2025 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $190.00Morgan Stanley raised their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday.February 28, 2025 | marketbeat.comAxsome Therapeutics price target raised to $190 from $125 at Morgan StanleyFebruary 27, 2025 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Lowered by Phocas Financial Corp.Phocas Financial Corp. trimmed its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 85.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,652 shares of the company's stock afterFebruary 27, 2025 | marketbeat.comAxsome Therapeutics to Participate in Upcoming Investor ConferencesFebruary 26, 2025 | markets.businessinsider.comAxsome Therapeutics price target raised to $212 from $195 at MizuhoFebruary 26, 2025 | markets.businessinsider.comMizuho Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock PriceMizuho boosted their price objective on Axsome Therapeutics from $195.00 to $212.00 and gave the stock an "outperform" rating in a report on Wednesday.February 26, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 203,672 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Principal Financial Group Inc. raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 6,002.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 207,065 shares of the company's stock afteFebruary 26, 2025 | marketbeat.comAxsome Therapeutics Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 24, 2025 | finance.yahoo.comAxsome Therapeutics says SYMBRAVO achieves primary endpoint in EMERGE trialFebruary 24, 2025 | markets.businessinsider.comTruist Financial Remains a Buy on Axsome Therapeutics (AXSM)February 24, 2025 | markets.businessinsider.comIFP Advisors Inc Purchases 18,038 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)IFP Advisors Inc lifted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 36.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 67,839 shares of the company's stock after acquiring an additional 18,038 shares during the period. IFebruary 24, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for AXSM FY2028 Earnings?Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2028 EPS estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Friday, February 21st. Leerink Partnrs analyst M. Goodman now anticipatesFebruary 24, 2025 | marketbeat.comQ1 EPS Forecast for Axsome Therapeutics Lowered by AnalystAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for Axsome Therapeutics in a research report issued on Thursday, February 20th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.06)February 24, 2025 | marketbeat.comWhy Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025February 23, 2025 | msn.comAxsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst UpgradeAxsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week High Following Analyst UpgradeFebruary 22, 2025 | marketbeat.comQ1 Earnings Estimate for AXSM Issued By HC WainwrightAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Axsome Therapeutics in a report issued on Thursday, February 20th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earningsFebruary 22, 2025 | marketbeat.comFY2025 EPS Estimate for Axsome Therapeutics Cut by AnalystAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now anticipates thFebruary 22, 2025 | marketbeat.com Remove Ads Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼1.240.63▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼89▲AXSM Articles Average Week Remove Ads Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ONC News BNTX News TEVA News SMMT News ITCI News MRNA News GMAB News RDY News VTRS News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AXSM Stock Free AXSM Stock Alerts